252 related articles for article (PubMed ID: 37470943)
21. Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis.
Xu H; Liu Z; Shi H; Wang C
BMC Cancer; 2020 Nov; 20(1):1051. PubMed ID: 33131491
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis.
Zhang S; Cheng T
Ann Med; 2024 Dec; 56(1):2337729. PubMed ID: 38569199
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
Li C; Fan H; Xiang Q; Xu L; Zhang Z; Liu Q; Zhang T; Ling J; Zhou Y; Zhao X; Cui Y
Breast Cancer Res Treat; 2019 Dec; 178(3):497-504. PubMed ID: 31471838
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis.
Liu M; Xiang Q; Dai F; Yuan Y; Wu Z; Xiang T
Clin Breast Cancer; 2024 May; ():. PubMed ID: 38821742
[TBL] [Abstract][Full Text] [Related]
25. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
Almstedt K; Heimes AS; Kappenberg F; Battista MJ; Lehr HA; Krajnak S; Lebrecht A; Gehrmann M; Stewen K; Brenner W; Weikel W; Rahnenführer J; Hengstler JG; Hasenburg A; Schmidt M
Eur J Cancer; 2022 Sep; 173():10-19. PubMed ID: 35839597
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of the Serum HER2 Extracellular Domain Level in Breast Cancer: A Systematic Review and Meta-Analysis.
Wu Y; Li L; Zhang D; Ma F
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230471
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis.
Schettini F; Martínez-Sáez O; Falato C; De Santo I; Conte B; Garcia-Fructuoso I; Gomez-Bravo R; Seguí E; Chic N; Brasó-Maristany F; Paré L; Vidal M; Adamo B; Muñoz M; Pascual T; Ciruelos E; Perou CM; Carey LA; Prat A
ESMO Open; 2023 Jun; 8(3):101214. PubMed ID: 37075698
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience.
Xu H; Han Y; Wu Y; Wang Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Ma F; Xu B; Wang J
Front Oncol; 2022; 12():906011. PubMed ID: 35785207
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.
Petrelli F; Viale G; Cabiddu M; Barni S
Breast Cancer Res Treat; 2015 Oct; 153(3):477-91. PubMed ID: 26341751
[TBL] [Abstract][Full Text] [Related]
30. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a meta-analysis including 5177 patients.
Zhao Z; Mu H; Li Y; Liu Y; Zou J; Zhu Y
Clin Transl Oncol; 2020 Oct; 22(10):1892-1906. PubMed ID: 32166713
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis.
Zhang Z; Li C; Fan H; Xiang Q; Xu L; Liu Q; Zhou S; Xie Q; Chen S; Mu G; Cui Y
Breast Cancer Res Treat; 2018 Dec; 172(3):513-521. PubMed ID: 30159787
[TBL] [Abstract][Full Text] [Related]
33. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
Eur J Cancer; 2022 Nov; 176():30-40. PubMed ID: 36183652
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China.
Dai Q; Feng K; Liu G; Cheng H; Tong X; Wang X; Feng L; Wang Y
Target Oncol; 2024 Jan; 19(1):81-93. PubMed ID: 38265547
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals.
Guo W; Lu X; Liu Q; Zhang T; Li P; Qiao W; Deng M
Cancer Med; 2019 Aug; 8(9):4135-4148. PubMed ID: 31197958
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic Features and Prognosis of Female Early Breast Cancer With HER2 Low Expression: A Propensity Score Matched Analysis.
Dai L; Huang Q; Guo R; Zhu K; Tang Y; Chen D; Huang S
Clin Med Insights Oncol; 2023; 17():11795549231202463. PubMed ID: 38023289
[TBL] [Abstract][Full Text] [Related]
37. Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis.
Petrelli F; Barni S
Med Oncol; 2012 Dec; 29(4):2586-93. PubMed ID: 22415399
[TBL] [Abstract][Full Text] [Related]
38. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
39. High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved.
Luo Y; Zhang X; Mo M; Tan Z; Huang L; Zhou H; Wang C; Wei F; Qiu X; He R; Chen G
Medicine (Baltimore); 2016 Apr; 95(15):e3337. PubMed ID: 27082587
[TBL] [Abstract][Full Text] [Related]
40. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]